The drug development process is slow and costly due to reliance on animal testing, which often proves ineffective or harmful in humans. We need a more efficient approach, like advanced in vitro modeling, for faster, safer drug development and personalized medicine. Organ-on-a-chip devices are a recent breakthrough in creating in vitro microphysiological systems that closely mimic human organ-level and organism-level functions. They replicate vital organ structures and physiological movements like breathing or peristalsis, providing an accurate model of organ function and diseases.
Progress in stem cell technology, including induced pluripotent stem (iPS) cells and organoids, allows the sourcing and differentiation of patient-specific stem cells for tailored preclinical models within this organ-on-a-chip. To advance in vitro modeling, it is crucial to understand the molecular differences in diseases. Proteins are the primary target for drugs, and proteomics is a vital tool in drug discovery because it can reveal the complex molecular details of diseases.
Combining organ-on-a-chip modeling with proteomics revolutionizes drug discovery and biomedical research. By incorporating proteomic analysis into these systems, we gain a comprehensive view of the proteins involved, providing valuable insights into cellular mechanisms, signaling pathways, and disease progression. Proteomic data from these models helps identify relevant biomarkers, potential drug targets, and understand drug-protein interactions. This integration enhances the accuracy of preclinical drug testing, accelerates therapeutic development, and ultimately holds the promise of personalized medicine by tailoring treatments to an individual's unique protein expression profile.
The aim of the current Research Topic is to cover promising, recent, and novel research trends in organ-on-a-chip modeling and its proteomics analysis for drug, therapeutic, and diagnosis discovery. Areas to be covered in this Research Topic may include, but are not limited to:
•Accelerating drug development through advanced organ-on-a-chip modeling.
•Incorporating patient-specific stem cells in organ-on-a-chip models for personalized preclinical drug testing (also including organoids).
•Preclinical drug testing accuracy through proteomic analysis in organ-on-a-chip models.
•Biomarker Discovery and Drug Target Identification in Organ-on-a-Chip Models through Proteomic Analysis
The drug development process is slow and costly due to reliance on animal testing, which often proves ineffective or harmful in humans. We need a more efficient approach, like advanced in vitro modeling, for faster, safer drug development and personalized medicine. Organ-on-a-chip devices are a recent breakthrough in creating in vitro microphysiological systems that closely mimic human organ-level and organism-level functions. They replicate vital organ structures and physiological movements like breathing or peristalsis, providing an accurate model of organ function and diseases.
Progress in stem cell technology, including induced pluripotent stem (iPS) cells and organoids, allows the sourcing and differentiation of patient-specific stem cells for tailored preclinical models within this organ-on-a-chip. To advance in vitro modeling, it is crucial to understand the molecular differences in diseases. Proteins are the primary target for drugs, and proteomics is a vital tool in drug discovery because it can reveal the complex molecular details of diseases.
Combining organ-on-a-chip modeling with proteomics revolutionizes drug discovery and biomedical research. By incorporating proteomic analysis into these systems, we gain a comprehensive view of the proteins involved, providing valuable insights into cellular mechanisms, signaling pathways, and disease progression. Proteomic data from these models helps identify relevant biomarkers, potential drug targets, and understand drug-protein interactions. This integration enhances the accuracy of preclinical drug testing, accelerates therapeutic development, and ultimately holds the promise of personalized medicine by tailoring treatments to an individual's unique protein expression profile.
The aim of the current Research Topic is to cover promising, recent, and novel research trends in organ-on-a-chip modeling and its proteomics analysis for drug, therapeutic, and diagnosis discovery. Areas to be covered in this Research Topic may include, but are not limited to:
•Accelerating drug development through advanced organ-on-a-chip modeling.
•Incorporating patient-specific stem cells in organ-on-a-chip models for personalized preclinical drug testing (also including organoids).
•Preclinical drug testing accuracy through proteomic analysis in organ-on-a-chip models.
•Biomarker Discovery and Drug Target Identification in Organ-on-a-Chip Models through Proteomic Analysis
